Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) Announces New Subsidiary, Provides Update on Nicotine Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has incorporated a new wholly owned subsidiary: Lexaria Nutraceutical Corp., or LEXX Nutra. According to the announcement, LEXX Nutra was established to support Lexaria’s overall strategy of maximizing the potential for its patented DehydraTECH(TM) technology in a variety of markets. The company issued an exclusive perpetual license to LEXX Nutra, giving the new subsidiary rights to utilize, or sublicense the use of, DehydraTECH in an array of ways, including creating consumer packaged goods (“CPG”) and/or intermediate ingredients composed of any molecule except those associated with nicotine or cannabis. LEXX Nutra is prohibited from using its license for the manufacture of any pharmaceutical product. The company also reported that dosing for its human oral nicotine study NIC-H22-1 was completed on May 8, 2023, and data amalgamation and analysis has started. Lexaria anticipates releasing results from the study in the next two weeks. The study is a human pharmacokinetic randomized, double-blinded, crossover study conducted with a minimum of 36 human volunteers who are current cigarette smokers.

To view the full press release, visit https://cnw.fm/BT3rZ

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Newly Granted Patent for DehydraTECH(TM)–Nicotine by United States Patent and Trademark Office

  • Lexaria’s new patent includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches
  • The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is expected to grow to $11.91 billion by 2029, driven by the growing ban on e-cigarettes worldwide
  • The white pouch category is one of the fastest-growing, tobacco-free alternatives to smoking and vaping – growing at a CAGR of 13.4%

Lexaria Bioscience (NASDAQ: LEXX), a global innovator of drug delivery platforms, has announced that the United States Patent and Trademark Office (“USPTO”) has granted a strategically important new patent in the oral nicotine sector for its patented DehydraTECH(TM) technology. The granting of the new patent further substantiates the superior DehydraTECH processing and sublingual compositions through exceptional scientific study results and recognition by the USPTO (https://cnw.fm/Sk9yh).

Lexaria’s new patent, US patent #11,700,875 Compositions and Methods For Sublingual Delivery of Nicotine, includes claims for many types of nicotine, including nicotine benzoate, nicotine ditartrate, nicotine citrate, nicotine polacrilex, and many others, for use in sublingual delivery formats like oral pouches. DehydraTECH-nicotine has shown in multiple sets of animal testing that it can be delivered to the bloodstream up to 10-times to 20-times faster at up to 10-fold higher levels of nicotine into blood plasma from oral absorption than concentration-matched controls. The speed of onset has proven vital to nicotine users.

The oral nicotine pouch category interests Lexaria and the nicotine products industry, growing partly because of its reduced risk of health outcomes, as the US Food and Drug Administration has previously noted. The white pouch delivery method specifically avoids harmful lung outcomes experienced by smokers or vapers. It involves absorption primarily through the buccal and sublingual tissues of the mouth of purified nicotine that has been separated from the harmful substances found in most other formats.

The global oral nicotine pouch market was valued at $4.69 billion in 2022 and is growing at a CAGR of 13.4% (https://cnw.fm/Hv5tb). By 2029, the market is expected to reach $11.91 billion – driven by multiple countries banning the sale of e-cigarettes, the devices used in vaping. Currently, 37 countries have banned these devices, representing a cumulative population of over 2.3 billion people (https://cnw.fm/SWyLu). The initial purpose of vaping was to help wean people off cigarette use, but it has become controversial and is limited in certain countries, with many restrictions and bans worldwide.

The US-granted patent is also progressing as a patent application through other jurisdictions internationally. The US patent and international patent applications are partly supported by the superior pharmacokinetic blood plasma data from Lexaria in its animal studies conducted from 2017 through 2021. This new patent builds nicely upon the company’s growing patent portfolio in the oral nicotine delivery sector, including the white pouch category for sublingual and buccal tissue delivery. The patents are built on a foundation of nicotine-specific patent filings dating back to 2019 and DehydraTECH patents dating back to 2016.

Lexaria’s DehydraTECH-nicotine has patents granted for oral nicotine delivery in the US, Canada, Australia, and is pending in numerous other countries. The white pouch category is one of the fastest growing, tobacco-free alternatives to smoking and vaping – emitting no smoke, odors, or vapors that can affect nearby persons and are a superior nicotine delivery method. Lexaria demonstrates this through its granted patents, subsequent studies, and future endeavors for sublingual and buccal delivery with DehydraTECH.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Study Shows Proximity Vital to Customers Buying Cannabis from Licensed Stores

Marijuana retailers are well aware of the fact that customers prefer to purchase cannabis from nearby sources when possible. This intuition is supported by a recent study on Canada’s legalized marijuana market, which shows that consumers are much more likely to purchase products from legal marketplaces if they are close to licensed retailers.

The research, which is slated for publication in the “Journal of Studies on Drugs and Alcohol,” explores the relationship between Canadian marijuana users’ proximity to authorized retail establishments and their decision to buy cannabis products. Notably, respondents were more likely to choose legal establishments and less likely to choose regulated internet sites if they lived within three kilometers (about 1.9 miles) of the closest permitted cannabis retailer.

The study, which examines data from 15,312 Canadian marijuana users who took part in the International Marijuana Policy Study, spans the years 2019 to 2021. The study uses postal codes, which are typically more precise than U.S. ZIP codes, to locate their locations. The investigation explored various sources from which cannabis users acquired marijuana, such as regulated and illicit stores, websites, dealers, home production, and family and friends.

Compared to those who lived farther away, those who lived within three kilometers of a physically permitted marijuana business were less likely to buy from licensed online retailers or raise their own plants.

Interestingly, a comparison between Quebec and Alberta shows that consumers’ satisfaction declines when marijuana stores get closer to one another. The private cannabis retail industry in Alberta had a significant ratio of 18.7 outlets per 100,000 persons by 2021, compared to just 0.8 stores in Quebec’s government-owned retail monopoly. Albertans are more likely to purchase from regulated stores, although the difference was just 1.6 times greater.

The study also discovered a rise in the percentage of respondents obtaining their cannabis through legal channels and a drop in those obtaining it illegally, which is consistent with Canada’s goals for legalizing recreational marijuana.

It’s worth noting that the three-kilometer distance doesn’t necessarily correspond to the actual travel distance from a respondent’s postal code to the closest retail outlet. Instead, it reflects a straight line.

Canada had more than 3,740 licensed marijuana retail establishments as of April 2023 across all of its provinces and territories, which equates to 0.95 cannabis outlets per 10,000 persons. Alberta continues to be the state with the most marijuana stores per capita.

The report also showed $3.4 billion worth of legal recreational marijuana was sold in 2022, a 17.9% rise over 2021. In contrast, medical marijuana sales have decreased from their high as a result of the spike in recreational cannabis spending since it cannot be purchased through adult-use retail stores.

While companies that sell recreational or medical cannabis have to compete with unlicensed dealers, enterprises that focus on FDA-approved formulations made from marijuana compounds, such as IGC Pharma Inc. (NYSE American: IGC), don’t have such concerns because their products are accessible from pharmacies if one gets a prescription from their doctor.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Ohio to Move Medical Cannabis Regulation Away from Board of Pharmacy

Ohio lawmakers have passed an operating budget with provisions that effectively remove the Board of Pharmacy as the entity in charge of the state’s cannabis industry and replace it with a new Division of Marijuana Control. The new regulatory agency for all cannabis-related matters will function under the auspices of the Ohio Department of Commerce.

Ever since former Ohio Governor John Kasich signed House Bill 523 into law and launched the state’s medical marijuana program, both the pharmacy and commerce departments had been tasked with overseeing the fledgling medical cannabis program. While the commerce department handled marijuana cultivators, processors and testing laboratories, the pharmacy department regulated retail operations and dispensaries as well as maintained Ohio’s registry of caregivers and medical marijuana patients.

Putting two departments in charge of medical cannabis proved to be a major headache for companies in Ohio’s medical cannabis market. These companies had to deal with both departments and all the bureaucracy that came with each. Large vertically integrated companies that were involved in cultivation, processing and sale had an especially challenging time dealing with both departments.

Ohio Medical Cannabis Industry Association’s government affairs director Charlie Trefny states that this system of shared governance would lead to disagreements due to different interpretations of rules. In some cases, Trefny says, the two departments would give cannabis companies different responses regarding the same issues. This includes providing conflicting feedback on critical issues such as product labeling, which could have dire consequences for medical cannabis operators.

Companies that aren’t vertically integrated were also forced to interact with both pharmacy and commerce. For instance, the pharmacy department would have to review labels attached to products from cultivators or processors resulting in cases where it would reject product labels that had been approved by the commerce department.

Medical cannabis operators have been asking regulators to grant the sector one regulator rather than two since its inception to make the regulatory environment more business-friendly. Trefny noted that consolidating regulation under a single department will make the medical cannabis supply chain more efficient as well.

According to language included in the recently approved operating budget, the pharmacy department will have to transfer its oversight of retailers, dispensaries and the state medical marijuana patient and caregiver registry to the commerce department by Dec. 31, 2023.

On the other hand, medical cannabis operators aren’t pleased with language included in the bill that would allow standalone processors to receive additional cultivation licenses and allow level 2 cultivators to expand their growing space to 15,000 square feet.

The improvements, which are likely to result from streamlining the regulation of medical cannabis in the state, could have additional benefits such as allowing ancillary firms operating in the same space, including Advanced Container Technologies Inc. (OTC: ACTX), to do brisk business with marijuana companies as demand grows.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Links Cannabis to Reduced Pain, Elevated Runner’s High

A recent study has unveiled a fascinating connection between marijuana usage and an enhanced exercise experience, particularly for runners. The study, conducted by researchers at the University of Colorado Boulder, focused on 49 runners. The individuals were asked to evaluate their running experiences under two conditions: one after consuming cannabis and the other without any marijuana intake.

The findings, recently published in the “Cannabis and Cannabinoid Research” journal, revealed that participants had significantly fewer negative emotions and greater feelings of positive affect, dissociation, enjoyment and tranquility during their marijuana-influenced runs compared to their nonmarijuana runs. Furthermore, the intriguing concept of a “runner’s high” was more pronounced when marijuana was involved.

Although the runners’ pace was slightly affected after consuming marijuana, the researchers deemed the decrease of 31 seconds per mile statistically insignificant. Surprisingly, the study revealed that pain levels were lower after the cannabis-influenced runs, while perceived exertion remained unchanged between the two conditions.

The implications of these results point to the possibility that acute marijuana use might contribute to a more gratifying exercise experience for regular marijuana users. Nevertheless, the researchers emphasized the need for further investigations encompassing diverse methodologies, exercise types and populations to ascertain the potential long-term benefits and risks associated with this behavior.

Interestingly, the positive exercise effects of cannabis align with the findings of an earlier study from 2019, which revealed that individuals using marijuana to enhance their workouts tend to engage in a more wholesome amount of physical activity.

In addition, an unrelated study in 2020 demonstrated that older individuals who consumed cannabis were more inclined to participate in physical activities. The study found that older marijuana users had lower BMI at the start of the study, participated in more exercise days and were involved in more exercises during the study period than their noncannabis user counterparts.

Breaking yet another stereotype, a 2021 study highlighted that frequent marijuana users are more likely to be physically active than their nonusing counterparts. This counters the notion that cannabis consumption leads to a sedentary lifestyle.

On another note, the use of medical marijuana has shown significant improvements in the quality of life for individuals with conditions such as insomnia and chronic pain. A 2023 study by the American Medical Association (AMA) found that the positive effects of medical cannabis were sustained over time. Late last year, the AMA also revealed study results linking state legalization of cannabis with a decline in the prescription of opioids to some cancer patients.

These studies attesting to the beneficial and therapeutic effects of cannabis are probably the grounds upon which many companies such as IGC Pharma Inc. (NYSE American: IGC) have focused on developing standardized medicinal formulations from THC and other cannabinoids so that patients can have access to effective cannabis-based treatments which are approved by the FDA.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Why Employers Are Ditching Pre-Employment Cannabis Testing

The changing legal framework surrounding marijuana makes it more difficult for companies to screen for marijuana-consuming applicants. According to an article by the Washington Post, the rapidly evolving state legislation concerning marijuana, combined with a shortage of eligible workers, has led to an increasing number of employers no longer requiring applicants to undergo a marijuana drug test as a condition for employment.

Amber Clayton, the senior director of knowledge center operations at the Society for Human Resource Management, explained that employers are grappling with the challenge of navigating these laws while ensuring the safety of their workforce. “We need to find a way to balance compliance with these laws while still maintaining a safe and productive work environment,” Clayton said.

Denise Polliciella, the founder and an attorney at Cannabis Attorneys of Michigan, voiced concerns over the exclusion of marijuana users from employment opportunities. She argued that many capable individuals are being sidelined unnecessarily, because marijuana use does not impede their job performance in any way.

Some employers, as reported by online work news platform Business, believe that eliminating mandatory marijuana drug tests could compromise workplace safety. This is due to the potential side effects of marijuana, such as hallucinations, disorientation, dizziness, fatigue and drowsiness.

Business noted that certain industries and professions, including school bus drivers, airline pilots and federal contractors, are heavily regulated, requiring drug testing for job candidates and employees. Marijuana is among the substances prohibited in these cases.

Michigan recently discontinued marijuana testing for most state jobs, with exceptions for law enforcement officers, healthcare providers and employees operating heavy machinery, according to CBS News.

According to the Pew Research Center, approximately 30% of U.S. adults support the legalization of marijuana for medical use, while 59% support its use for both medical and recreational purposes. Business highlighted the growing number of states, including the District of Columbia, three territories, and 37 states, that have legalized marijuana either for medical, recreational, or both purposes. This indicates a response to public demand.

Karger’s “Medical Cannabis and Cannabinoids” journal revealed that there are approximately 3.6 million legally registered medical cannabis patients alone. The Post mentioned that certain states have implemented laws to protect workers’ marijuana use during their personal time, leading some employers to consider excluding THC, the primary psychoactive component in cannabis, from their drug testing protocols, according to the National Library of Medicine.

As workplace rules evolve to accommodate workers who use marijuana, the demand for cannabis products is likely to grow as more employees feel comfortable using this substance for recreational or medicinal reasons. When this happens, the industry will grow faster, and entities such as Advanced Container Technologies Inc. (OTC: ACTX), which focus on addressing the needs of cultivators could see an uptick in their sales.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Set to be Used in Multi-Billion Dollar Markets; On Track to have 2023 as Best Year Yet

  • Lexaria’s patented DehydraTECH(TM) technology enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats
  • This unique approach to drug delivery has earned Lexaria a total of 35 patents, with many patents pending worldwide
  • The company continues active discussions with multi-billion dollar companies for the potential use of DehydraTECH in their commercial pursuits
  • Lexaria is also actively seeking commercial partners during 2023 and 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is out on an ambitious move to address conditions with high unmet needs. This focus has allowed them to make strides in the potential treatment of conditions such as hypertension, epilepsy, human hormone delivery, and nicotine replacement; all made possible through its patented technology, DehydraTECH(TM).

DehydraTECH enhances the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats. The technology serves as an additional step that can be easily incorporated into any formulation and manufacturing process, allowing for speedy delivery, an increase in bioavailability, and an increase in brain absorption, among other advantages (https://cnw.fm/LyMIC).

Lexaria’s studies have demonstrated a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,700 percent, which has opened the technology up to new possibilities for improved drug delivery.

One stand-out feature of DehydraTECH is its ability to work symbiotically with existing physiological systems to enable masking oral and olfactory receptors, rendering DehydraTECH-processed compounds mostly flavorless and odorless. This results in formulations not requiring sweeteners or chemical masking agents for flavor and odor blocking, meaning that manufacturers can create low-sugar products with fewer calories while avoiding excessive artificial sweeteners.

Once ingested, the compounds, through the help of fatty acids, permeate the intestinal wall for the active payload, then are transported to the systemic circulation by one of two pathways, typically dependent on the type of fatty acid(s) chosen for a given formulation. For hepatic transport, or where liver metabolism is desirable for biotransformation of the payload, Lexaria’s methodology uses medium-chain fatty acids. For lymphatic transport, on the other hand, Lexaria uses long-chain fatty acids, which are absorbed via the lymphatic lacteals, ultimately diverting them away from the liver and entering the general circulation very quickly.

DehydraTECH and its unique approach to drug delivery have earned Lexaria a current total of 35 patents across the United States, Canada, Mexico, Australia, Japan, India, and the European Union. Although it has already achieved considerable intellectual property protection through its existing patent portfolio, the company has a number of additional patents pending worldwide. These achievements have sparked interest across various industries. Lexaria’s CEO, Chris Bunka, has noted the company’s active discussions with multi-billion dollar companies for the potential use of its technology in their commercial product pursuits.

“Our applied R&D is paying off in spades because we are currently in active discussions with several multi-billion dollar companies around the world for the potential use of Lexaria’s DehydraTECH technology in their commercial product pursuits,” noted Mr. Bunka.

“These discussions are ongoing and have thus helped us to meet one of our primary objectives of the last year, which is to introduce DehydraTECH to world-leading potential collaborators,” he added (https://cnw.fm/yQagb).

Lexaria is ambitious in its push for DehydraTECH and is currently seeking commercial partners to use the technology in what are usually multi-billion-dollar markets. The company is taking steps to have multiple choices in how to fund its operations, and so far, it is on track to have 2023 as its best year ever.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Ohio Adds IBS to Medical Cannabis Qualifying Conditions List

Regulators in Ohio have added irritable bowel syndrome (IBS) to the state’s medical marijuana list of qualifying conditions. During the recent Ohio State Medical Board meeting, lawmakers made irritable bowel syndrome the 26th qualifying condition for a medical marijuana license in the state.

IBS is one of the most common chronic conditions in America, affecting an estimated 25  to 45 million people in the country and costing the U.S. a whopping $1.3 billion in medical costs annually. The chronic condition is characterized by symptoms such as abdominal pain, diarrhea, cramping, gas and bloating, and affects roughly 5% to 10% of the global population.

According to Charlie Trefny, the director of government affairs at the Ohio Medical Cannabis Industry Association, adding IBS to the Ohio list of qualifying conditions for medical marijuana will “expand patient access” and help numerous Ohio residents living with the chronic condition.

Experts break irritable bowel syndrome into three categories: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D) and IBS with mixed bowel habits (IBS-M).

A report from the Columbus Dispatch notes that while people with chronic IBS could already access medical cannabis because of chronic pain, the addition of IBS to the list of qualifying conditions will make medical cannabis accessible to significantly more IBS patients.

However, the board refused to add autism to the list of approved conditions for the third time. Trefny noted that she was disappointed in the board for not approving the addition of obsessive-compulsive disorder (OCD) and autism spectrum disorder.

A recent bill introduced by Senators Kirk Schuring and Stephen Huffman represented the fourth time the Ohio State Medical Board received a petition to allow people with autism to access medical cannabis. The measure would also allow medical cannabis patients to use therapeutic oral pouches, strips, sprays, pills, suppositories and capsules, topical salves, sprays and lotions as well as inhalers.

At the moment, Ohio allows patients with the following conditions to access medical cannabis: Alzheimer’s disease, AIDS, Amyotrophic lateral sclerosis (ALS), cancer, cachexia, Crohn’s disease, chronic traumatic encephalopathy, epilepsy or seizure disorders, glaucoma, fibromyalgia, Huntington’s disease, multiple sclerosis and sickle cell anemia. If Senate Bill 9 is successful, it will add autism, migraines, chronic muscle spasms or spasticity, opioid use disorder and terminal illness to the list of qualifying conditions.

Ohio also permits medical cannabis access to patients with severe intractable or chronic pain, Parkinson’s disease, spasticity, terminal illness, ulcerative colitis, Tourette syndrome and traumatic brain injuries.

As more patients use marijuana to treat or manage their ailments, entities such as IGC Pharma Inc. (NYSE American: IGC) are seeking to up the ante by developing standardized formulations from cannabis that meet the FDA regulatory requirements so that these treatments can be available nationwide through the healthcare system.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Meta to Let Hemp and CBD Firms Advertise on IG, Facebook

CBD and hemp firms recently scored a major win after Facebook’s parent company Meta loosened its hemp and cannabis advertising policies. In a recent notice, Meta announced the changes to its advertising policies and noted that companies in the cannabis space would now be allowed to advertise non-ingestible cannabidiol products under certain limitations. The social media giant also said that CBD-infused products that have 0.3% or less of THC can be promoted on its platforms if those products meet certain conditions.

America’s state-level cannabis industry has been incredibly lucrative from its inception, generating billions of dollars in sales and creating hundreds of thousands of new job opportunities. However, since the plant is illegal at the federal level and classified as a Schedule I controlled drug with no medical application, America’s cannabis industry is severely limited.

One of the most significant limitations is that the players in the cannabis sector are prohibited from advertising their products on most conventional platforms, making it extremely difficult for them to attract customers and boost sales.

With Meta’s recent announcement, hemp and cannabis retailers will be able to promote their products to the billions of consumers that use platforms such as Facebook, Instagram and recent addition Threads. Cannabis businesses will require written approval from parent company Meta as well as proof that their products are compliant with local laws and certified with Legitscript before they can prompt their products on Meta platforms.

Furthermore, the social media conglomerate has revised its hemp advertising policies to allow hemp businesses to promote their goods on Meta in the Canada, Mexico, and U.S. markets as long as they comply with local laws, industry guidelines and codes. Businesses will not require written permission to promote products with less than the legal threshold for THC (0.3%) in these three markets.

Meta will also publish hemp-related ads that seek to educate the public, advocate for or give “public service announcements related to CBD” without the need for written permission as long as they do not promote prohibited products.

The company said in a statement that it wants people to discover new products and services and learn about them on its platforms. Meta cautioned that ads containing CBD products will not be allowed to state or claim that the products can prevent, treat, cure, diagnose or mitigate any medical issue in humans and animals. Additionally, Meta’s ban on advertising THC-containing products or psychoactive cannabis products will remain active, the company said.

As more cannabis companies gain access to running adverts on various social media platforms, the industry is likely to grow, and this growth could deepen the reach of ancillary companies such as Advanced Container Technologies Inc. (OTC: ACTX), which indirectly benefit from the progress registered by cannabis enterprises.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — BJS Report Reveals a 61% Reduction in Marijuana Incarcerations as State-Level Legalization Spreads

A recent report from the Bureau of Justice Statistics (BJS) has revealed significant developments in drug-related incarcerations within the federal prison system. The number of individuals imprisoned for marijuana offenses dropped by a remarkable 61%, surpassing reductions seen in other drug categories between 2013 and 2018.

Overall, drug-related incarcerations in federal prisons decreased by 24% during the same timeframe. However, the report highlights that nearly one-half of the Bureau of Prisons’ population in 2018 consisted of individuals impacted by the war on drugs.

While marijuana cases saw the most substantial decline at 61%, powder and crack cocaine incarcerations also significantly decreased by 35% and 45%, respectively, over the five-year period. Opioid-related incarcerations experienced a more modest decline of 4%. According to the report, the reductions in drug-related incarcerations were partially offset by an increase in individuals serving sentences for methamphetamine and heroin offenses, which rose by 12% and 13%, respectively.

The BJS report states that the majority of individuals incarcerated for drug-related convictions in federal prison were involved in trafficking rather than simple possession. However, there was also a notable decline in possession-related incarcerations.

The number of nontrafficking drug offenders dropped sharply from 2013, when there were about 500 people, to only 54 prisoners by 2018, representing less than 0.1% of the total federal prison population. In contrast, drug trafficking offenses constituted a significant portion of the incarcerated population, with 71,500 individuals behind bars for these crimes in 2018, accounting for almost one-half of all Bureau of Prisons detainees.

Racial demographics showed that Hispanic individuals comprised the majority (59.3%) of those incarcerated for cannabis offenses, followed by white individuals at 19.3% and Black individuals at 18.4%.

It’s important to consider that the data in the report only extends until 2018, and since then, more state markets have embraced legalization while law enforcement priorities have continued to evolve. In subsequent years, the U.S. Sentencing Commission (USSC) tracked federal drug-trafficking cases up to 2022 and reported a sustained decline in the number of federal cannabis trafficking offenders, from 5000 in 2013 to 800 in 2022. However, trafficking cases involving substances such as methamphetamine, fentanyl and powder cocaine increased during this period.

Additional data from Customs and Border Protection (CBP) revealed a record-low number of cannabis seizures in 2022, reflecting the impact of state-level legalization efforts on enforcement practices. Moreover, a 2022 Government Accountability Office (GAO) report shed light on enforcement activities, indicating that seizures primarily involved small quantities of marijuana from American citizens rather than large-scale operations involving international cartels at checkpoints.

The reduced incarceration rates suggest that society and the criminal justice system is evolving in the way it views marijuana, and the work being undertaken by enterprises such as IGC Pharma Inc. (NYSE American: IGC) could further accelerate this shift as more pharmaceutical-grade formulations from THC win FDA approval.

NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.